Do I need a prescription for Ethanol 20% solution for injection 10ml ampoules?

Ethanol 20% solution for injection 10ml ampoules is classified as a Valid as a prescribable product in the UK. However, always consult a pharmacist or doctor before use. (Source: NHS dm+d)

What are the brand names for Ethanol 20% solution for injection 10ml ampoules?

Ethanol 20% solution for injection 10ml ampoules is the generic name. It is available under brand names including: Ethanol 20% solution for injection 10ml ampoules. (Source: NHS dm+d — Actual Medicinal Products)

Ethanol 20% solution for injection 10ml ampoules

Prescription only

Requires a prescription from a doctor or prescriber

Injection

20%

Parenteral

Oral liquids

A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body.

Active ingredients:

Ethanol

Chemical classBrowse classes

Classification based on the molecule's chemical structure and properties

Check interactions for Ethanol

No active safety alerts

Official documents, adverse reaction reporting, and safety monitoring

Report a side effect

Submit a Yellow Card report to the MHRA

Official medicine documents

Yellow Card

Report side effects (MHRA)

Drug safety updates

MHRA alerts for Ethanol

Source: MHRA Products DatabaseOGL 3.0

Updated 3 months ago(16 Jan 2026)

Safety monitoring data

Yellow Card reports

MHRA

The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.

View Drug Analysis Profile

Suspected adverse reactions reported for Ethanol

Browse all iDAP reports

Interactive Drug Analysis Profiles for all medicines

Report a side effect

Submit a Yellow Card report to the MHRA

Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.

EudraVigilance

EMA

The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.

View EudraVigilance report

Suspected adverse reactions reported for Ethanol

About EudraVigilance

Learn about EU pharmacovigilance and safety monitoring

EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.

1 branded products available

1 productsShow details

1 products

Possibly available on the UK marketRestricted supplyDiscontinuedAvailability per NHS dm+d

MHRA licensed products

View all licensed products for Ethanol on the MHRA register

Ethanol 20% solution for injection 10ml ampoules

Special Order

None

Special

Source: NHS dm+dOGL 3.0

Updated about 1 month ago(1 Mar 2026)

Clinical guidelines and formulary information

British National Formulary

Ethanol

BNF

Drug monograph — bnf.nice.org.uk

Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.

NICE clinical guidance(10)

Microwave ablation of hepatocellular carcinoma (HTG138)

HTG138

Guidance

Updated Mar 2007

Ultrasound-guided percutaneous radiofrequency ablation for benign thyroid nodules (HTG416)

HTG416

Guidance

Updated Jun 2016

Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules (HTG646)

HTG646

Guidance

Updated Nov 2022

High-intensity focused ultrasound for symptomatic benign thyroid nodules (HTG504)

HTG504

Guidance

Updated Feb 2019

Irreversible electroporation for primary liver cancer (HTG532)

HTG532

Guidance

Updated Nov 2019

Laparoscopic liver resection (HTG83)

HTG83

Guidance

Updated Jul 2005

Thoracoscopic excision of mediastinal parathyroid tumours (HTG159)

HTG159

Guidance

Updated Dec 2007

Image-guided percutaneous laser ablation for primary and secondary liver tumours (HTG722)

HTG722

Guidance

Updated May 2024

Lower urinary tract symptoms in men: management (CG97)

CG97

Clinical guideline

Updated Jun 2015

Thyroid disease: assessment and management (NG145)

NG145

NICE guideline

Updated Oct 2023

Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.

Check stock at pharmacies and supply information

Show details

Pharmacy stock checkers

Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.

Boots

Search products

Click & collectNHS

Lloyds

Search products

DeliveryNHS

P2U

Pharmacy2U

Search products

DeliveryNHS

Supply & product information

Official product databases and supply status monitoring

Shortages info

NHS Specialist Pharmacy Service (SPS)

emc product search

Discontinuations & alternatives for Ethanol

Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.

Codes for healthcare professionals and prescribing systems

Show details

These codes are used by healthcare IT systems and prescribers to identify this medicine.

NHS UK identifiers

SNOMED CT

20492911000001101

dm+d ID

20492911000001101

VTM (Virtual Therapeutic Moiety)

775880004

VMP (Virtual Medicinal Product)

20492911000001101

SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA).

Active and completed clinical studies from ClinicalTrials.gov

Show details

Searching UK clinical trials...

Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.

Pharmacology and chemical data from DrugBank

go.drugbank.com

Key facts

Drug status

Approved

Major interactions

75 found

Half-life

Not available

Mechanism

Ethanol affects the brain’s neurons in several ways.

Food interactions

None known

Human targets

54 targets

Data: DrugBank · CC BY-NC 4.0

Pharmacokinetics at a glance

Absorption

Rapidly absorbed.

Metabolism

Hepatic. Metabolized by cytochrome P450 enzyme CYP2E1.

Pharmacokinetic data: DrugBank · CC BY-NC 4.0

Status:

Approved

Investigational

Small molecule

About this compound

A clear, colorless liquid rapidly absorbed from the gastrointestinal tract and distributed throughout the body. It has bactericidal activity and is used often as a topical disinfectant. It is widely used as a solvent and preservative in pharmaceutical preparations as well as serving as the primary ingredient in alcoholic beverages.

Properties:

liquid

Avg. mass: 46.07 Da

DrugBank indication

For therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (tic douloureux), in patients for whom neurosurgical procedures are contraindicated.

Also known as(318)

1-Hydroxyethane

Alcohol

Alcohol (ethyl)

Alcohol anhydrous

Alcohol denatured

Alcohol etílico

Alcohol, denatured

Alcool éthylique

Dosage forms(2324)

Solution (Topical) — 80 % w/w

Gel (Topical) — 62 mL/1

Spray (Topical) — 3028 mL/3785mL

Cloth (Extracorporeal) — 3 mL/1

Gel (Topical) — 36.7 mL/59.2mL

Solution (Topical) — 70 mL/70mL

Liquid (Topical) — 62 mL/1

Liquid (Topical) — 73.7 mL/100mL

Molecular properties(19)

Drug interactions(1543)

Known interactions with other medications. Always consult a healthcare professional.

Cilostazol

Unknown severity

DB01166

The serum concentration of Cilostazol can be increased when it is combined with Ethanol.

Check this interaction

Deferasirox

Unknown severity

DB01609

The serum concentration of Ethanol can be increased when it is combined with Deferasirox.

Check this interaction

Peginterferon alfa-2b

Unknown severity

DB00022

The serum concentration of Ethanol can be increased when it is combined with Peginterferon alfa-2b.

Check this interaction

Leflunomide

Unknown severity

DB01097

The serum concentration of Ethanol can be decreased when it is combined with Leflunomide.

Check this interaction

Teriflunomide

Unknown severity

DB08880

The serum concentration of Ethanol can be decreased when it is combined with Teriflunomide.

Check this interaction

Metyrosine

Moderate

DB00765

Ethanol may increase the sedative activities of Metyrosine.

Check this interaction

Minocycline

Moderate

DB01017

Minocycline may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Pramipexole

Moderate

DB00413

Ethanol may increase the sedative activities of Pramipexole.

Check this interaction

Ropinirole

Moderate

DB00268

Ethanol may increase the sedative activities of Ropinirole.

Check this interaction

Thalidomide

Unknown severity

DB01041

The risk or severity of somnolence and peripheral neuropathy can be increased when Thalidomide is combined with Ethanol.

Check this interaction

Eliglustat

Moderate

DB09039

The metabolism of Eliglustat can be decreased when combined with Ethanol.

Check this interaction

Ibrutinib

Moderate

DB09053

The metabolism of Ibrutinib can be decreased when combined with Ethanol.

Check this interaction

Colchicine

Moderate

DB01394

The metabolism of Colchicine can be decreased when combined with Ethanol.

Check this interaction

Fentanyl

Moderate

DB00813

Fentanyl may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Retapamulin

Moderate

DB01256

The metabolism of Retapamulin can be decreased when combined with Ethanol.

Check this interaction

Tofacitinib

Moderate

DB08895

The metabolism of Tofacitinib can be decreased when combined with Ethanol.

Check this interaction

Vardenafil

Moderate

DB00862

The metabolism of Vardenafil can be decreased when combined with Ethanol.

Check this interaction

Lovastatin

Moderate

DB00227

The metabolism of Lovastatin can be decreased when combined with Ethanol.

Check this interaction

Methadone

Unknown severity

DB00333

The risk or severity of adverse effects can be increased when Methadone is combined with Ethanol.

Check this interaction

Alfuzosin

Moderate

DB00346

The metabolism of Alfuzosin can be decreased when combined with Ethanol.

Check this interaction

Memantine

Unknown severity

DB01043

The risk or severity of adverse effects can be increased when Ethanol is combined with Memantine.

Check this interaction

Ifosfamide

Moderate

DB01181

The metabolism of Ifosfamide can be increased when combined with Ethanol.

Check this interaction

Warfarin

Unknown severity

DB00682

The serum concentration of Warfarin can be increased when it is combined with Ethanol.

Check this interaction

Acenocoumarol

Unknown severity

DB01418

The serum concentration of Acenocoumarol can be increased when it is combined with Ethanol.

Check this interaction

(R)-warfarin

Unknown severity

DB08496

The serum concentration of (R)-warfarin can be increased when it is combined with Ethanol.

Check this interaction

R,S-Warfarin alcohol

Unknown severity

DB08735

The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Ethanol.

Check this interaction

S,R-Warfarin alcohol

Unknown severity

DB08736

The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Ethanol.

Check this interaction

(S)-Warfarin

Unknown severity

DB14055

The serum concentration of (S)-Warfarin can be increased when it is combined with Ethanol.

Check this interaction

Atorvastatin

Moderate

DB01076

The metabolism of Atorvastatin can be decreased when combined with Ethanol.

Check this interaction

Procarbazine

Unknown severity

DB01168

The risk or severity of adverse effects can be increased when Procarbazine is combined with Ethanol.

Check this interaction

Abiraterone

Unknown severity

DB05812

The serum concentration of Ethanol can be increased when it is combined with Abiraterone.

Check this interaction

Lithium citrate

Unknown severity

DB14507

The risk or severity of adverse effects can be increased when Ethanol is combined with Lithium citrate.

Check this interaction

Pimavanserin

Moderate

DB05316

The metabolism of Pimavanserin can be increased when combined with Ethanol.

Check this interaction

Botulinum toxin type B

Moderate

DB00042

Botulinum toxin type B may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Botulinum toxin type A

Moderate

DB00083

Botulinum toxin type A may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Tryptophan

Moderate

DB00150

Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Fluvoxamine

Moderate

DB00176

Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Baclofen

Moderate

DB00181

Baclofen may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Lorazepam

Moderate

DB00186

Lorazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Ethchlorvynol

Moderate

DB00189

Ethchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Tramadol

Moderate

DB00193

Tramadol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Succinylcholine

Moderate

DB00202

Succinylcholine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Reserpine

Moderate

DB00206

Reserpine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Citalopram

Moderate

DB00215

Citalopram may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Eletriptan

Moderate

DB00216

Eletriptan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Enflurane

Moderate

DB00228

Enflurane may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Pregabalin

Moderate

DB00230

Pregabalin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Temazepam

Moderate

DB00231

Temazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Reboxetine

Moderate

DB00234

Reboxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Butabarbital

Moderate

DB00237

Butabarbital may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Check this interaction

Showing 50 of 1543 interactions

Toxicity & overdose

Oral, rat LD₅₀: 5628 mg/kg. Symptoms and effects of overdose include nausea, vomiting, CNS depression, acute respiratory failure or death and with chronic use, severe health problems, such as liver and brain damage.

How it works

Mechanism of action

Ethanol affects the brain’s neurons in several ways. It alters their membranes as well as their ion channels, enzymes, and receptors. Alcohol also binds directly to the receptors for acetylcholine, serotonin, GABA, and the NMDA receptors for glutamate.
The sedative effects of ethanol are mediated through binding to GABA receptors and glycine receptors (alpha 1 and alpha 2 subunits). It also inhibits NMDA receptor functioning. In its role as an anti-infective, ethanol acts as an osmolyte or dehydrating agent that disrupts the osmotic balance across cell membranes.

Pharmacodynamics

Alcohol produces injury to cells by dehydration and precipitation of the cytoplasm or protoplasm. This accounts for its bacteriocidal and antifungal action. When alcohol is injected in close proximity to nerve tissues, it produces neuritis and nerve degeneration (neurolysis). Ninety to 98% of ethanol that enters the body is completely oxidized. Ethanol is also used as a cosolvent to dissolve many insoluble drugs and to serve as a mild sedative in some medicinal formulations. Ethanol also binds to GABA, glycine, NMDA receptors and modulates their effects. Ethanol is also metabolised by the hepatic enzyme alcohol dehydrogenase.

Pharmacokinetics

How the body processes this drug — absorption, distribution, metabolism, and elimination

Absorption

Rapidly absorbed.

Metabolism

Hepatic. Metabolized by cytochrome P450 enzyme CYP2E1.

Drug targets(54)

Proteins and enzymes this drug interacts with in the body

Gamma-aminobutyric acid receptor subunit alpha-1

BE0000795

GABRA1

agonist

Specific functionGABA-A receptor activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Alpha subunit of the heteropentameric ligand-gated chloride channel gated by Gamma-aminobutyric acid (GABA), a major inhibitory neurotransmitter in the brain .
PMID:23909897 PMID:25489750 PMID:29950725 PMID:30602789

GABA-gated chloride channels, also named GABA(A) receptors (GABAAR), consist of five subunits arranged around a central pore and contain GABA active binding site(s) located at the alpha and beta subunit interface(s) .
PMID:29950725 PMID:30602789
When activated by GABA, GABAARs selectively allow the flow of chloride anions across the cell membrane down their electrochemical gradient .
PMID:23909897 PMID:29950725 PMID:30602789

Alpha-1/GABRA1-containing GABAARs are largely synaptic (By similarity). Chloride influx into the postsynaptic neuron following GABAAR opening decreases the neuron ability to generate a new action potential, thereby reducing nerve transmission (By similarity). GABAARs containing alpha-1 and beta-2 or -3 subunits exhibit synaptogenic activity; the gamma-2 subunit being necessary but not sufficient to induce rapid synaptic contacts formation .
PMID:23909897 PMID:25489750
GABAARs function also as histamine receptor where histamine binds at the interface of two neighboring beta subunits and potentiates GABA response (By similarity).

GABAARs containing alpha, beta and epsilon subunits also permit spontaneous chloride channel activity while preserving the structural information required for GABA-gated openings (By similarity). Alpha-1-mediated plasticity in the orbitofrontal cortex regulates context-dependent action selection (By similarity). Together with rho subunits, may also control neuronal and glial GABAergic transmission in the cerebellum (By similarity)

Glutamate receptor ionotropic, NMDA 3A

BE0000641

GRIN3A

antagonist

Specific functioncalcium channel activity

Cellular location

Cell membrane

General function & pharmacology

Component of a non-conventional N-methyl-D-aspartate (NMDA) receptors (NMDARs) that function as heterotetrameric, ligand-gated cation channels with low calcium permeability and low voltage-dependent block by Mg(2+) (By similarity). During the development of neural circuits, participates in the synaptic refinement period, restricting spine maturation and growth (By similarity). Forms glutamatergic receptor complexes with GluN1 and GluN2 subunits which are activated by glycine binding to the GluN1 and GluN3 subunits and L-glutamate binding to GluN2 subunits (By similarity).

Forms excitatory glycinergic receptor complexes with GluN1 alone which are activated by glycine binding to the GluN1 and GluN3 subunits .
PMID:38598639
GluN3A subunit also binds D-serine (By similarity). Each GluN3 subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, Ca2(+) permeability, and binding to allosteric modulators (By similarity). By competing with GIT1 interaction with ARHGEF7/beta-PIX, may reduce GIT1/ARHGEF7-regulated local activation of RAC1, hence affecting signaling and limiting the maturation and growth of inactive synapses (By similarity)

Glycine receptor subunit alpha-1

BE0000433

GLRA1

agonist

Specific functionextracellularly glycine-gated chloride channel activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Subunit of heteromeric glycine-gated chloride channels .
PMID:14551753 PMID:23994010 PMID:25730860 PMID:37821459

Plays an important role in the down-regulation of neuronal excitability .
PMID:8298642 PMID:9009272
Contributes to the generation of inhibitory postsynaptic currents .
PMID:25445488
Channel activity is potentiated by ethanol .
PMID:25973519
Potentiation of channel activity by intoxicating levels of ethanol contribute to the sedative effects of ethanol (By similarity)

Glycine receptor subunit alpha-2

BE0000745

GLRA2

agonist

Specific functionextracellularly glycine-gated chloride channel activity

Cellular location

Postsynaptic cell membrane

General function & pharmacology

Subunit of heteromeric glycine-gated chloride channels .
PMID:15302677 PMID:16144831 PMID:2155780 PMID:23895467 PMID:25445488 PMID:26370147 PMID:34473954

Plays a role in synaptic plasticity (By similarity). Contributes to the generation of inhibitory postsynaptic currents, and is involved in the down-regulation of neuronal excitability .
PMID:25445488
Plays a role in cellular responses to ethanol PMID:23895467

Voltage-dependent L-type calcium channel subunit beta-1

BE0000303

CACNB1

inhibitor

Specific functioncalcium channel regulator activity

Cellular location

Cell membrane, sarcolemma

General function & pharmacology

Regulatory subunit of L-type calcium channels .
PMID:1309651 PMID:15615847 PMID:8107964

Regulates the activity of L-type calcium channels that contain CACNA1A as pore-forming subunit (By similarity). Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit and increases the presence of the channel complex at the cell membrane .
PMID:15615847
Required for functional expression L-type calcium channels that contain CACNA1D as pore-forming subunit .
PMID:1309651
Regulates the activity of L-type calcium channels that contain CACNA1B as pore-forming subunit PMID:8107964

Metabolizing enzymes(16)

Enzymes involved in drug metabolism — important for understanding drug interactions

Enzyme activity key

substrate

inhibitor

inducer

CYP1A1Cytochrome P450 1A1

inhibitor

CYP1A2Cytochrome P450 1A2

substrate

CYP2B6Cytochrome P450 2B6

inhibitor

CYP2C9Cytochrome P450 2C9

inhibitor

CYP2C19Cytochrome P450 2C19

inhibitor

CYP2E1Cytochrome P450 2E1

substrate

inducer

CYP3A4Cytochrome P450 3A4

substrate

inhibitor

inducer

CYP4A11Cytochrome P450 4A11

inducer

ADH1AAlcohol dehydrogenase 1A

substrate

ADH1BAll-trans-retinol dehydrogenase [NAD(+)] ADH1B

substrate

ADH1CAlcohol dehydrogenase 1C

substrate

ADH5Alcohol dehydrogenase class-3

substrate

ADH4All-trans-retinol dehydrogenase [NAD(+)] ADH4

substrate

ADH7All-trans-retinol dehydrogenase [NAD(+)] ADH7

substrate

ADH6Alcohol dehydrogenase 6

substrate

AKR1A1Aldo-keto reductase family 1 member A1

substrate

Biological pathways(2)

Scientific references(5)

Snyder R., Kalf G.F.

A Perspective on Benzene Leukemogenesis.

Critical Reviews in Toxicology

199424(3):177-209. doi: 10.3109/10408449409021605

PMID: 7945890 DOI: 10.3109/10408449409021605

Chastain G.

Alcohol, Neurotransmitter Systems, and Behavior.

The Journal of General Psychology

2006133(4):329-335. doi: 10.3200/genp.133.4.329-335

PMID: 17128954 DOI: 10.3200/genp.133.4.329-335

McDonnell G., Russell A.D.

Antiseptics and Disinfectants: Activity, Action, and Resistance.

Clinical Microbiology Reviews

199912(1):147-179. doi: 10.1128/cmr.12.1.147

PMID: 9880479 DOI: 10.1128/cmr.12.1.147

Barceloux D.G., Bond G.R., Krenzelok E.P., Cooper H., Vale J.A.

American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Methanol Poisoning.

Journal of Toxicology: Clinical Toxicology

200240(4):415-446. doi: 10.1081/clt-120006745

PMID: 12216995 DOI: 10.1081/clt-120006745

Hingson R., Winter M.

Age of first intoxication, heavy drinking, driving after drinking and risk of unintentional injury among U.

college students.. Journal of Studies on Alcohol. 200364(1):23-31. doi: 10.15288/jsa.2003.64.23

PMID: 15301401 DOI: 10.15288/jsa.2003.64.23

ATC classification(3 codes)

ATC V03AB16

ATC V03AZ01

ATC D08AX08

Affected organisms(1)

Humans and other mammals

International brands(1)

Experimental properties(5)

External resources(2)

RxList Drugs.com

Protein Data Bank entries(299)

Commercial products(22382)

Chemical identifiers

CAS, UNII, InChI Key and database cross-references

Show

Linked compound data from DrugBank Open Data (CC BY-NC 4.0)

Ethanol

DB00898

CAS number

64-17-5

UNII (FDA)

3K9958V90M

InChI Key (molecular fingerprint)

LFQSCWFLJHTTHZ-UHFFFAOYSA-N

Additional database identifiers

Drugs Product Database (DPD)

8890

Drugs Product Database (DPD)

3438

ChEBI

16236

PubChem Compound

702

PubChem Substance

46506969

KEGG Compound

C00469

KEGG Drug

D00068

ChemSpider

682

PharmGKB

PA448073

PDB

EOH

Therapeutic Targets Database

DAP000681

IUPHAR

2299

Guide to Pharmacology

2299

Wikipedia

Ethanol

ChEMBL

CHEMBL545

RxCUI

448

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4075

GenAtlas

GABRA1

GeneCards

GABRA1

GenBank Gene Database

X13584

GenBank Protein Database

31631

IUPHAR

404

Guide to Pharmacology

404

UniProtKB

P14867

UniProt Accession

GBRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:16767

GenAtlas

GRIN3A

GeneCards

GRIN3A

GenBank Gene Database

AJ416950

GenBank Protein Database

20372905

IUPHAR

460

UniProtKB

Q8TCU5

UniProt Accession

NMD3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4326

GenAtlas

GLRA1

GeneCards

GLRA1

GenBank Gene Database

X52009

GenBank Protein Database

31851

IUPHAR

423

Guide to Pharmacology

423

UniProtKB

P23415

UniProt Accession

GLRA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4327

GenAtlas

GLRA2

GeneCards

GLRA2

GenBank Gene Database

X52008

GenBank Protein Database

31849

IUPHAR

424

Guide to Pharmacology

424

UniProtKB

P23416

UniProt Accession

GLRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1401

GenAtlas

CACNB1

GeneCards

CACNB1

GenBank Gene Database

M92303

GenBank Protein Database

179806

UniProtKB

Q02641

UniProt Accession

CACB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5297

GenAtlas

HTR3A

GeneCards

HTR3A

GenBank Gene Database

D49394

GenBank Protein Database

681914

IUPHAR

373

Guide to Pharmacology

373

UniProtKB

P46098

UniProt Accession

5HT3A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4076

GenAtlas

GABRA2

GeneCards

GABRA2

GenBank Gene Database

S62907

GenBank Protein Database

386422

IUPHAR

405

Guide to Pharmacology

405

UniProtKB

P47869

UniProt Accession

GBRA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:13800

GenAtlas

CHRNA10

GeneCards

CHRNA10

GenBank Gene Database

AJ278118

GenBank Protein Database

12053839

IUPHAR

470

Guide to Pharmacology

470

UniProtKB

Q9GZZ6

UniProt Accession

ACH10_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1390

GenAtlas

CACNA1C

GeneCards

CACNA1C

GenBank Gene Database

M92270

IUPHAR

529

Guide to Pharmacology

529

UniProtKB

Q13936

UniProt Accession

CAC1C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4079

GenAtlas

GABRA5

GeneCards

GABRA5

GenBank Gene Database

L08485

GenBank Protein Database

182916

IUPHAR

408

Guide to Pharmacology

408

UniProtKB

P31644

UniProt Accession

GBRA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4078

GenAtlas

GABRA4

GeneCards

GABRA4

GenBank Gene Database

U30461

GenBank Protein Database

905393

IUPHAR

407

Guide to Pharmacology

407

UniProtKB

P48169

UniProt Accession

GBRA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4077

GenAtlas

GABRA3

GeneCards

GABRA3

GenBank Gene Database

S62908

GenBank Protein Database

386424

IUPHAR

406

Guide to Pharmacology

406

UniProtKB

P34903

UniProt Accession

GBRA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4571

GenAtlas

GRIA1

GeneCards

GRIA1

GenBank Gene Database

M64752

GenBank Protein Database

183281

IUPHAR

444

Guide to Pharmacology

444

UniProtKB

P42261

UniProt Accession

GRIA1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1405

GenAtlas

CACNG1

GeneCards

CACNG1

GenBank Gene Database

L07738

GenBank Protein Database

306473

UniProtKB

Q06432

UniProt Accession

CCG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1956

GenAtlas

CHRNA2

GeneCards

CHRNA2

GenBank Gene Database

U62431

GenBank Protein Database

1458110

IUPHAR

463

Guide to Pharmacology

463

UniProtKB

Q15822

UniProt Accession

ACHA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4080

GenAtlas

GABRA6

GeneCards

GABRA6

GenBank Gene Database

S81944

GenBank Protein Database

1470364

IUPHAR

409

Guide to Pharmacology

409

UniProtKB

Q16445

UniProt Accession

GBRA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4572

GenAtlas

GRIA2

GeneCards

GRIA2

GenBank Gene Database

L20814

GenBank Protein Database

493134

IUPHAR

445

Guide to Pharmacology

445

UniProtKB

P42262

UniProt Accession

GRIA2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4574

GenAtlas

GRIA4

GeneCards

GRIA4

GenBank Gene Database

U16129

GenBank Protein Database

790538

IUPHAR

447

Guide to Pharmacology

447

UniProtKB

P48058

UniProt Accession

GRIA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4573

GenAtlas

GRIA3

GeneCards

GRIA3

GenBank Gene Database

U10302

GenBank Protein Database

507829

IUPHAR

446

Guide to Pharmacology

446

UniProtKB

P42263

UniProt Accession

GRIA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1958

GenAtlas

CHRNA4

GeneCards

CHRNA4

GenBank Gene Database

L35901

GenBank Protein Database

755648

IUPHAR

465

Guide to Pharmacology

465

UniProtKB

P43681

UniProt Accession

ACHA4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1962

GenAtlas

CHRNB2

GeneCards

CHRNB2

GenBank Gene Database

X53179

GenBank Protein Database

32017

IUPHAR

472

UniProtKB

P17787

UniProt Accession

ACHB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6264

GenAtlas

KCNJ3

GeneCards

KCNJ3

GenBank Gene Database

U39196

GenBank Protein Database

1055028

IUPHAR

434

Guide to Pharmacology

434

UniProtKB

P48549

UniProt Accession

KCNJ3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6267

GenAtlas

KCNJ6

GeneCards

KCNJ6

GenBank Gene Database

U24660

GenBank Protein Database

1052875

IUPHAR

435

Guide to Pharmacology

435

UniProtKB

P48051

UniProt Accession

KCNJ6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:12663

GenAtlas

VCAM1

GeneCards

VCAM1

GenBank Gene Database

M30257

GenBank Protein Database

179886

UniProtKB

P19320

UniProt Accession

VCAM1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11003

GenAtlas

SLC29A1

GeneCards

SLC29A1

GenBank Gene Database

U81375

GenBank Protein Database

1845345

Guide to Pharmacology

1117

UniProtKB

Q99808

UniProt Accession

S29A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6266

GenAtlas

KCNJ5

GeneCards

KCNJ5

GenBank Gene Database

U39195

GenBank Protein Database

1055026

IUPHAR

437

Guide to Pharmacology

437

UniProtKB

P48544

UniProt Accession

KCNJ5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1960

GenAtlas

CHRNA7

GeneCards

CHRNA7

GenBank Gene Database

X70297

GenBank Protein Database

496607

IUPHAR

468

Guide to Pharmacology

468

UniProtKB

P36544

UniProt Accession

ACHA7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14079

GenAtlas

CHRNA9

GeneCards

CHRNA9

GenBank Gene Database

AJ243342

GenBank Protein Database

6688136

IUPHAR

469

Guide to Pharmacology

469

UniProtKB

Q9UGM1

UniProt Accession

ACHA9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4081

GenAtlas

GABRB1

GeneCards

GABRB1

GenBank Gene Database

X14767

GenBank Protein Database

31635

IUPHAR

410

UniProtKB

P18505

UniProt Accession

GBRB1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4083

GenAtlas

GABRB3

GeneCards

GABRB3

GenBank Gene Database

M82919

GenBank Protein Database

182925

IUPHAR

412

Guide to Pharmacology

412

UniProtKB

P28472

UniProt Accession

GBRB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4082

GenAtlas

GABRB2

GeneCards

GABRB2

GenBank Gene Database

S67368

GenBank Protein Database

455946

IUPHAR

411

UniProtKB

P47870

UniProt Accession

GBRB2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1397

GenAtlas

CACNA1S

GeneCards

CACNA1S

GenBank Gene Database

U30707

GenBank Protein Database

1698403

IUPHAR

528

Guide to Pharmacology

528

UniProtKB

Q13698

UniProt Accession

CAC1S_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1391

GenAtlas

CACNA1D

GeneCards

CACNA1D

GenBank Gene Database

M76558

GenBank Protein Database

179764

IUPHAR

530

Guide to Pharmacology

530

UniProtKB

Q01668

UniProt Accession

CAC1D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1964

GeneCards

CHRNB4

GenBank Gene Database

U62439

GenBank Protein Database

1458126

UniProtKB

P30926

UniProt Accession

ACHB4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1957

GeneCards

CHRNA3

GenBank Gene Database

M86383

GenBank Protein Database

177898

Guide to Pharmacology

464

UniProtKB

P32297

UniProt Accession

ACHA3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1959

GeneCards

CHRNA5

GenBank Gene Database

M83712

GenBank Protein Database

177926

UniProtKB

P30532

UniProt Accession

ACHA5_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:15963

GeneCards

CHRNA6

GenBank Gene Database

U62435

GenBank Protein Database

1458118

Guide to Pharmacology

467

UniProtKB

Q15825

UniProt Accession

ACHA6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1963

GeneCards

CHRNB3

GenBank Gene Database

U62438

GenBank Protein Database

1458124

UniProtKB

Q05901

UniProt Accession

ACHB3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4086

GeneCards

GABRG1

GenBank Gene Database

AK122845

GenBank Protein Database

193783776

UniProtKB

Q8N1C3

UniProt Accession

GBRG1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4088

GeneCards

GABRG3

GenBank Gene Database

S82769

GenBank Protein Database

1754749

UniProtKB

Q99928

UniProt Accession

GBRG3_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4085

GeneCards

GABRE

GenBank Gene Database

U66661

GenBank Protein Database

1857126

UniProtKB

P78334

UniProt Accession

GBRE_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4089

GeneCards

GABRP

GenBank Gene Database

U95367

GenBank Protein Database

2197001

UniProtKB

O00591

UniProt Accession

GBRP_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:14454

GeneCards

GABRQ

GenBank Gene Database

AF189259

GenBank Protein Database

7861736

UniProtKB

Q9UN88

UniProt Accession

GBRT_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:4084

GeneCards

GABRD

GenBank Gene Database

AF016917

GenBank Protein Database

2388693

UniProtKB

O14764

UniProt Accession

GBRD_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:11004

GeneCards

SLC29A2

UniProtKB

Q14542

UniProt Accession

S29A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24005

GeneCards

HTR3E

UniProtKB

A5X5Y0

UniProt Accession

5HT3E_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:5298

GeneCards

HTR3B

Guide to Pharmacology

374

UniProtKB

O95264

UniProt Accession

5HT3B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24004

GeneCards

HTR3D

UniProtKB

Q70Z44

UniProt Accession

5HT3D_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:24003

GeneCards

HTR3C

UniProtKB

Q8WXA8

UniProt Accession

5HT3C_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:1406

GeneCards

CACNG2

UniProtKB

Q9Y698

UniProt Accession

CCG2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6270

GeneCards

KCNJ9

UniProtKB

Q92806

UniProt Accession

KCNJ9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:6470

GeneCards

L1CAM

UniProtKB

P32004

UniProt Accession

L1CAM_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:108

GenAtlas

ACHE

GeneCards

ACHE

GenBank Gene Database

M55040

GenBank Protein Database

177975

Guide to Pharmacology

2465

UniProtKB

P22303

UniProt Accession

ACES_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:256

GenAtlas

ADH7

GeneCards

ADH7

GenBank Gene Database

L33179

GenBank Protein Database

516618

UniProtKB

P40394

UniProt Accession

ADH7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2595

GeneCards

CYP1A1

GenBank Gene Database

K03191

GenBank Protein Database

181276

Guide to Pharmacology

1318

UniProtKB

P04798

UniProt Accession

CP1A1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2596

GenAtlas

CYP1A2

GeneCards

CYP1A2

GenBank Gene Database

Z00036

Guide to Pharmacology

1319

UniProtKB

P05177

UniProt Accession

CP1A2_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2615

GeneCards

CYP2B6

GenBank Gene Database

M29874

GenBank Protein Database

181296

Guide to Pharmacology

1324

UniProtKB

P20813

UniProt Accession

CP2B6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2623

GenAtlas

CYP2C9

GeneCards

CYP2C9

GenBank Gene Database

AY341248

Guide to Pharmacology

1326

UniProtKB

P11712

UniProt Accession

CP2C9_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2621

GeneCards

CYP2C19

GenBank Gene Database

M61854

GenBank Protein Database

181344

Guide to Pharmacology

1328

UniProtKB

P33261

UniProt Accession

CP2CJ_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2631

GeneCards

CYP2E1

GenBank Gene Database

J02625

GenBank Protein Database

181360

Guide to Pharmacology

1330

UniProtKB

P05181

UniProt Accession

CP2E1_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2637

GenAtlas

CYP3A4

GeneCards

CYP3A4

GenBank Gene Database

M18907

Guide to Pharmacology

1337

UniProtKB

P08684

UniProt Accession

CP3A4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:2642

GenAtlas

CYP4A11

GeneCards

CYP4A11

GenBank Gene Database

L04751

GenBank Protein Database

181397

Guide to Pharmacology

1341

UniProtKB

Q02928

UniProt Accession

CP4AB_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:249

GenAtlas

ADH1A

GeneCards

ADH1A

GenBank Gene Database

M12271

GenBank Protein Database

178092

UniProtKB

P07327

UniProt Accession

ADH1A_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:250

GenAtlas

ADH1B

GeneCards

ADH1B

GenBank Gene Database

M24317

GenBank Protein Database

178098

UniProtKB

P00325

UniProt Accession

ADH1B_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:251

GenAtlas

ADH1C

GeneCards

ADH1C

GenBank Gene Database

X04299

GenBank Protein Database

28404

UniProtKB

P00326

UniProt Accession

ADH1G_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:253

GenAtlas

ADH5

GeneCards

ADH5

GenBank Gene Database

M30471

GenBank Protein Database

178134

UniProtKB

P11766

UniProt Accession

ADHX_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:252

GenAtlas

ADH4

GeneCards

ADH4

GenBank Gene Database

M15943

GenBank Protein Database

178121

UniProtKB

P08319

UniProt Accession

ADH4_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:256

GenAtlas

ADH7

GeneCards

ADH7

GenBank Gene Database

L33179

GenBank Protein Database

516618

UniProtKB

P40394

UniProt Accession

ADH7_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:255

GeneCards

ADH6

GenBank Gene Database

AK092768

GenBank Protein Database

193787401

UniProtKB

P28332

UniProt Accession

ADH6_HUMAN

HUGO Gene Nomenclature Committee (HGNC)

HGNC:380

GeneCards

AKR1A1

GenBank Gene Database

J04794

GenBank Protein Database

178481

UniProtKB

P14550

UniProt Accession

AK1A1_HUMAN

International reference pricing

3 formulations

Reference pricing from DrugBank. Prices are indicative and may not reflect current UK costs.

From $0.02/ml

To $7.80/ml

Alcohol, denatured

$0.02/ml

Alcohol, dehydrated 98% amp

$4.68/ml

Ethanol 98% ampul

$7.80/ml

Source: DrugBank. Used under CC BY-NC 4.0 academic licence for non-commercial purposes.

Patent information

All patents expired, 3 expired

6036976

United States

Approved 14 Mar 2000 · Expires 13 Dec 2016

Expired

7081246

United States

Approved 25 Jul 2006 · Expires 3 Aug 2016

Expired

5897031

United States

Approved 27 Apr 1999 · Expires 21 Jun 2016

Expired

Patent protection has expired — generic versions may be available.

Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.

DrugBank citations

If you use DrugBank data in your research, please cite the following publications:

Knox C., Wilson M., Klinger C.M., et al

DrugBank 6.

0: the DrugBank Knowledgebase for 2024

Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275

PMID: 37953279

Wishart D.S., Feunang Y.D., Guo A.C., et al

DrugBank 5.

0: a major update to the DrugBank database for 2018

Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082

PMID: 29126136

Show earlier publications

Law V., Knox C., Djoumbou Y., et al

DrugBank 4.

0: shedding new light on drug metabolism

Nucleic Acids Res. 2014 Jan 142(1):D1091-7

PMID: 24203711

Knox C., Law V., Jewison T., et al

DrugBank 3.

0: a comprehensive resource for 'omics' research on drugs

Nucleic Acids Res. 2011 Jan39(Database issue):D1035-41

PMID: 21059682

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a knowledgebase for drugs, drug actions and drug targets.

Nucleic Acids Research

2008 Jan36(Database issue):D901-6

PMID: 18048412

Wishart D.S., Knox C., Guo A.C., et al

DrugBank: a comprehensive resource for in silico drug discovery and exploration.

Nucleic Acids Research

2006 Jan 134(Database issue):D668-72

PMID: 16381955

Source: go.drugbank.comCC BY-NC 4.0

Updated 27 days ago(8 Mar 2026)

Back to medicines

Ethanol 20% solution for injection 10ml ampoules

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

British National Formulary

NICE clinical guidance(10)

Pharmacy stock checkers

Supply & product information

NHS UK identifiers

Key facts

Pharmacokinetics at a glance

Absorption

Metabolism

Clinical essentials

Pharmacology

Deep science
72

Chemical identifiers

Ethanol

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Ethanol 20% solution for injection 10ml ampoules

Safety & regulatory

Official medicine documents

Safety monitoring data

Yellow Card reports

EudraVigilance

Brand versions and licensed products

Guidance (NICE / BNF)

British National Formulary

NICE clinical guidance(10)

Availability, stocks & shortages

Pharmacy stock checkers

Supply & product information

Professional identifiers

NHS UK identifiers

Clinical trials

DrugBank data

Key facts

Pharmacokinetics at a glance

Absorption

Metabolism

Clinical essentials

Pharmacology

Deep science72

Chemical identifiers

Ethanol

Additional database identifiers

International reference pricing

Patent information

DrugBank citations

Deep science
72